sprifermin
Recombinant proteinexperimental
Sprifermin is a recombinant human fibroblast growth factor 18 (rhFGF18) analog, originally developed by Merck, and now being further developed by TrialSpark’s subsidiary, High Line Bio, for the treatment of osteoarthritis. FGF18 and sprifermin act via the Fibroblast Growth Factor Receptor (FGFR) family, with preferential activity via FGFR3c. — Wikipedia
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00911469)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor 18Supplementation
FGF18 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSprifermin ↗
- ChEMBLCHEMBL2108302 ↗
Also known as
- as902330
- fgf-18
- fgf-18 protein, human
- fgf18 protein, human
- fgf-18 protein, mouse
- fgf18 protein, mouse
- fgf-18 protein, rat
- fgf18 protein, rat
- fibroblast growth factor 18
- fibroblast growth factor 18, human
- fibroblast growth factor 18, mouse
- fibroblast growth factor 18, rat
- sprifermin
- sprifermin
- sprifermin
- sprifermin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01919164 | Phase 2 | Jul 1, 2013 | Merck Serono, Nordic Bioscience |
| NCT01689337 | Phase 2 | Apr 1, 2013 | Merck Serono |
| NCT01066871 | Phase 2 | Mar 1, 2010 | Merck KGaA |
| NCT01033994 | Phase 1 | Oct 1, 2008 | Merck KGaA, Merck Serono |
| NCT00911469 | Phase 1 | Nov 1, 2007 | Merck KGaA, Merck Serono |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck Serono | For profit | 4 | 2 | 2 | 2007 |
| Merck KGaA | For profit | 3 | 3 | 2 | 2007 |
| Nordic Bioscience | For profit | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1